DBV Technologies Stock: -16% in Three Months, Eyeing Support at €3.19
The French biotech is losing ground in a downward trending Parisian market. The stock has fallen below its short-term moving averages after a recent, short-lived rebound.
The stock falls below its short-term moving averages and moves away from the €3.85 resistance
DBV Technologies' stock has declined by 2.4% to €3.25, down from €3.33 at the previous close. This movement occurs in a SBF 120 that is down by 1% and a CAC 40 which is down by 1.05%. The Ile-de-France-based biotech has broken through its 20-day moving average set at €3.40, now 4.41% above the current price, and remains below its 50-day moving average at €3.47. The RSI at 47 indicates a neutral configuration, without a marked buying dynamic.
The stock is approaching its support at €3.19, while the resistance at €3.85 remains out of reach. Today's decline brings the three-month performance to -15.8%, but the annual performance remains largely positive at +117.2%, supported by the crossing of the 200-day moving average at €2.91 (the price is 11.68% above this long-term reference). The stock is in a consolidation phase after several sessions of fluctuating around €3.40.
Solid Cash Reserves Until Q2 2027 and Two Major FDA Filings on the Horizon
Beyond the stock movement, the biotech's horizon is shaped by its regulatory calendar. The company reported on May 1st a cash reserve of $229 million as of March 31st, sufficient to finance its operations until the second quarter of 2027. The group also plans to submit two biologics license applications in 2026 to the FDA for its Viaskin Peanut allergen patch, one for ages 4-7 and another for ages 1-3. A phase 2 study in infants is also expected.
On the analyst side, Kempen lowered its price target from €11 to €9 at the beginning of May while maintaining a buy recommendation, which suggests significant appreciation potential compared to the current level. The support at €3.19 is the next reference level to watch in the upcoming sessions.
